Abeona inks licensing agreement with Regenxbio

6 November 2018

US gene therapy developer Abeona Therapeutics (Nasdaq: ABEO) says that it has been granted new exclusive licenses to develop gene therapies for treatment of four rare lysosomal storage disorders using US biotech Regenxbio’s (Nasdaq: RGNX) NAV AAV9 vector platform technology.

These global licenses will help support development of gene therapies for treatment of Sanfilippo syndrome types A and B (MPS IIIA and MPSIIIB), infantile Batten disease (CLN1) and juvenile Batten disease (CLN3).

News of the deal failed to excite markets, with Regenxbio dipping 0.93% to $69.94, and Abeona gained just 0.22% to $9.25 by close of trading on Monday. Investors appear disappointed that Regenxbio did not receive a higher financial commitment in the deal considering only $40 million is assured, according to a posting on the Seeking Alpha blog.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK